|Nf1-dependent tumors require a microenvironment containing Nf1+/−-and c-kit-dependent bone marrow|
FC Yang, DA Ingram, S Chen, Y Zhu, J Yuan, X Li, X Yang, S Knowles, ...
Cell 135 (3), 437-448, 2008
|Neighborhood socioeconomic disadvantage and 30-day rehospitalization: a retrospective cohort study|
AJH Kind, S Jencks, J Brock, M Yu, C Bartels, W Ehlenbach, C Greenberg, ...
Annals of internal medicine 161 (11), 765-774, 2014
|CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis|
L Wang, Z Zhao, MB Meyer, S Saha, M Yu, A Guo, KB Wisinski, W Huang, ...
Cancer cell 25 (1), 21-36, 2014
|Joint longitudinal-survival-cure models and their application to prostate cancer|
M Yu, NJ Law, JMG Taylor, HM Sandler
Statistica Sinica, 835-862, 2004
|Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis|
S Seng, Z Liu, SK Chiu, T Proverbs-Singh, G Sonpavde, TK Choueiri, ...
J clin oncol 30 (35), 4416-26, 2012
|Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor|
RJ Chan, MB Leedy, V Munugalavadla, CS Voorhorst, Y Li, M Yu, ...
Blood 105 (9), 3737-3742, 2005
|Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial|
KA Robertson, G Nalepa, FC Yang, DC Bowers, CY Ho, GD Hutchins, ...
The lancet oncology 13 (12), 1218-1224, 2012
|Advanced cognitive training for breast cancer survivors: a randomized controlled trial|
D Von Ah, JS Carpenter, A Saykin, P Monahan, J Wu, M Yu, G Rebok, ...
Breast cancer research and treatment 135 (3), 799-809, 2012
|Autotaxin expression and its connection with the TNF-alpha-NF-κB axis in human hepatocellular carcinoma|
JM Wu, Y Xu, NJ Skill, H Sheng, Z Zhao, M Yu, R Saxena, MA Maluccio
Molecular cancer 9 (1), 71, 2010
|Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial|
AM Moore, LH Einhorn, D Estes, R Govindan, J Axelson, J Vinson, ...
Lung Cancer 52 (1), 93-97, 2006
|Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis|
SG Zhao, SL Chang, DE Spratt, N Erho, M Yu, HAD Ashab, M Alshalalfa, ...
The lancet oncology 17 (11), 1612-1620, 2016
|Measurements of , Ką, KS0, Λ and proton produ ction in proton– carbon intera ctions at 31 GeV/ c with the NA61/SHINE spe ctrometer at the CERN SPS|
N Abgrall, A Aduszkiewicz, Y Ali, E Andronov, T Antićić, N Antoniou, ...
The European Physical Journal C 76 (2), 84, 2016
|Individualized predictions of disease progression following radiation therapy for prostate cancer.|
J Taylor, M Yu, HM Sandler
|Individual prediction in prostate cancer studies using a joint longitudinal survival–cure model|
M Yu, JMG Taylor, HM Sandler
Journal of the American Statistical Association 103 (481), 178-187, 2008
|Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells|
X Wu, SA Estwick, S Chen, M Yu, W Ming, TD Nebesio, Y Li, J Yuan, ...
Human molecular genetics 15 (19), 2837-2845, 2006
|Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or …|
SI Jalal, HD Riggs, A Melnyk, D Richards, A Agarwala, M Neubauer, ...
Annals of oncology 23 (7), 1730-1738, 2012
|Dose–volume analysis of radiation pneumonitis in non–small-cell lung cancer patients treated with concurrent cisplatinum and etoposide with or without consolidation docetaxel|
RB Barriger, AJ Fakiris, N Hanna, M Yu, P Mantravadi, RC McGarry
International Journal of Radiation Oncology* Biology* Physics 78 (5), 1381-1386, 2010
|Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy|
SG Zhao, SL Chang, N Erho, M Yu, J Lehrer, M Alshalalfa, C Speers, ...
JAMA oncology 3 (12), 1663-1672, 2017
|Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer|
MD Galsky, NM Hahn, T Powles, BA Hellerstedt, SP Lerner, TA Gardner, ...
Clinical genitourinary cancer 11 (2), 175-181, 2013
|Bias and efficiency loss due to categorizing an explanatory variable|
JMG Taylor, M Yu
Journal of Multivariate Analysis 83 (1), 248-263, 2002